Jan 07, 2026
Home Depot Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Home Depot. Looking at options history for Home Depot (NYSE:HD) we detected 27 trades. If we consider the specifics of each trade, it is accurate…

Jan 07, 2026
Price Over Earnings Overview: Manulife Financial

In the current market session, Manulife Financial Inc. (NYSE:MFC) stock price is at $37.24, after a 0.43% decrease. However, over the past month, the company's stock spiked by 3.24%, and in the past year, by 22.99%. Shareholders might be interested…

Jan 07, 2026
Why Wells Fargo’s Next Chapter Could Reward Investors

Wells Fargo & Company (NYSE:WFC) drew fresh investor focus Wednesday as Wall Street weighed the bank's post-asset-cap trajectory. Wells Fargo started a new chapter last year following the removal of the 2018 Fed-imposed asset cap (along with several other regulatory…

Jan 07, 2026
Market Whales and Their Recent Bets on TGT Options

Financial giants have made a conspicuous bullish move on Target. Our analysis of options history for Target (NYSE:TGT) revealed 22 unusual trades. Delving into the details, we found 45% of traders were bullish, while 40% showed bearish tendencies. Out of…

Jan 07, 2026
Smart Money Is Betting Big In RCL Options

High-rolling investors have positioned themselves bearish on Royal Caribbean Gr (NYSE:RCL), and it's important for retail traders to take note. This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors…

Jan 07, 2026
A Look Into Kenvue Inc’s Price Over Earnings

In the current session, Kenvue Inc. (NYSE:KVUE) is trading at $16.69, after a 0.36% decrease. Over the past month, the stock decreased by 3.39%, and in the past year, by 19.75%. With performance like this, long-term shareholders are more likely…

Jan 07, 2026
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

On Tuesday, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines. The acquisition values Dark Blue Therapeutics at up to $840 million, including upfront and future milestones. Why Is The Acquisition…

Jan 07, 2026
CoStar Rolls Out $1.5 Billion Buyback, Targets Record EBITDA In 2026

CoStar Group, Inc. (NASDAQ:CSGP) on Wednesday outlined its key business, financial, and governance initiatives for 2026 and beyond. Also, the company approved a new $1.5 billion share repurchase program, following the accelerated completion of the $500 million buyback in 2025.…